Ezz Life Science Holdings Ltd. · ASX:EZZ
Ezz Life Science — FY2024 Earnings Presentation
21 slides from Ezz Life Science's earnings presentation, Aug 28, 2024
Slide 1: FY24 Results Presentation
FY24 Results Presentation Glenn Cross, Non-Executive Director and Chair Tony Guarna, Chief Financial Officer ASX: EZZ
Slide 2: Disclaimer
Disclaimer This document has been prepared by EZZ Life Science Holdings Limited ACN 608 363 604 (Company). By accepting a copy of this document you warrant and undertake to the Company that you agree to be bound by the terms and conditions set out below. This document is not a prospectus, product di
Slide 3: Contents
Contents Contents • FY24 Highlights • FY24 Financial Performance • Company Strategy • Looking Forward • Q&A ASX: EZZ FY24 Full Year Results Presentation 3
Slide 4: FY24 Highlights
FY24 Highlights Strong Financial New Distribution New Product Performance Channels and Development Geographical Markets Strong revenue growth of 21 new products launched 79% from $37.1m in FY23 Strong growth on the under the EZZ brand in to $66.4m in FY24 Douyin and Tmall Global FY24 and distributed
Slide 5: FY24 Financial Performance
FY24 Financial Performance ASX: EZZ FY24 Full Year Results Presentation 5
Slide 6: FY24 Financial Overview
FY24 Financial Overview Revenue EBITDA Cash on Hand $66.4M $10.4M $19.0M Up by 78.9% YoY Up by 103.80% YoY No external debt Gross Margin NPAT Dividend 75%+ $6.9M 1.5 cents Steady for the period Up by 91.8% YoY 1H FY24 Interim ASX: EZZ FY24 Full Year Results Presentation 6
Slide 7: Revenue
Revenue Record revenue growth due to successful market-driven R&D, dynamic channel prioritisation, and targeted B2C marketing Revenue Drivers Revenue by Segment FY23 FY24 $62.6M $32.5M $4.6M $3.9M EZZ EAORON ASX: EZZ FY24 Full Year Results Presentation 7
Slide 8: Margins
Margins Attractive gross margin are well maintained and improving Gross Margin FY23 FY24 84% 80% 77% 77% 25% 26% EZZ EAORON Total ASX: EZZ FY24 Full Year Results Presentation 8
Slide 9: Profitability
Profitability Solid operating profit and strong growth momentum fuelled by successful investments in marketing EBITDA (Excluding Other Income) Operating Expense Breakdown $10.1M 5.7% 8.5% Others 3.1% Employee benefits 0.9% 4.8% $4.8M Depreciation and 1% amortisation Advertising and 90.3% marketing $
Slide 10: Working Capital
Working Capital Well maintained working capital position to accelerate continuous growth Working Capital Movements ASX: EZZ FY24 Full Year Results Presentation 10
Slide 11: Cash Flow
Cash Flow Cash flow from operating activities has more than doubled from a year ago Cash Flow Movements . ASX: EZZ FY24 Full Year Results Presentation 11
Slide 12: Revenue Mix
Revenue Mix Increasingly diversified revenue streams across multiple distribution channels and geographic regions Revenue by Channel Revenue by Geography 1.2% 1.0% 3.0% eCommerce 7.7% Greater China 17.0% Pharmacy / specialist Australia retailer New Zealand Supermarket / grocery store and Others othe
Slide 13: Financial Position
Financial Position Cash on hand Debt1 $19.0M $0 1 Excluding lease liabilities ASX: EZZ FY24 Full Year Results Presentation 13
Slide 14: Company Strategy
Company Strategy ASX: EZZ FY24 Full Year Results Presentation 14
Slide 15: The EZZ Mission
The EZZ Mission To become a leading life science company in the Asia-Pacific, improving quality of life and human health by accelerating innovation to market. ASX: EZZ FY24 Full Year Results Presentation 15
Slide 16: Company Pillars
Company Pillars Life Science Technology Distribution Consumers Product development pipeline Online store and data backed Focus on top-tier distributors Connection to consumers to increasingly feature analytical capabilities enable in target markets with proven through omnichannel healthcare solution
Slide 17: Diverse Product Range
Diverse Product Range We formulate, produce, market and distribute health supplements under the We are an exclusive distributor of skin care products under the EÁORON brand of EZZ. Our deep understanding of our target consumers allows us to brand in Australia and New Zealand to pharmacies, supermark
Slide 18: Extensive Distribution Capabilities
Extensive Distribution Capabilities Strong omnichannel marketing capabilities have delivered results Chemists Specialist and Grocery Retailers E-commerce Platforms 600+ 200+ 750+ ASX: EZZ FY24 Full Year Results Presentation 18
Slide 19: Looking Forward
Looking Forward • US market entry: EZZ has established a TikTok store and engaged relevant third-party partners to support ’ US to commence sales in Q2 FY25. • New products: EZZ expects to launch 10 new products in 1H FY25 in addition to the four functional food products announced in Q1 FY25. • Chin
Slide 20: Q&A
Q&A ASX: EZZ FY24 Full Year Results Presentation 20
Slide 21: EZZ Life Science Contact
EZZ Life Science Contact EZZ Life Science Holdings Limited Holdings Limited ABN 83 608 363 604 ASX: EZZ 104 Derby Street, Silverwater NSW 2128 T: 02 9160 2305 E: ir@ezzlife.com.au www.ezzlife.com.au EZZLifescience linkedin.com/company/ezz- EZZAustralia EZZ_Australia life-science-holdings FY24 Full Y
Ezz Life Science Holdings — FY2024 Earnings Presentation on 6ix